# Cetuximab for Elderly Patients With mCRC

> **NCT01718808** · PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01718808
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2015-12
- **Final completion:** 2017-01
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** FU for 3 years from randomization as initially planned is stopped as we do not expect any changes to the endpoints in the future after one year of FU.
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01718808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01718808, "Cetuximab for Elderly Patients With mCRC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01718808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*